Trillium Asset Management LLC Makes New $6.11 Million Investment in Merit Medical Systems, Inc. $MMSI

Key Points

• Trillium Asset Management acquired 88,038 Merit Medical Systems shares worth approximately $6.11 million, representing a 0.15% stake. Institutional investors collectively own 99.66% of the company.
• Merit Medical reported quarterly EPS of $1.19, exceeding estimates of $0.96, while revenue rose 9.5% year over year to $418.84 million. The company issued fiscal 2026 EPS guidance of $4.25–$4.35.
• Analyst sentiment remains positive, with eight Buy ratings and four Holds; the stock has a “Moderate Buy” consensus and an average price target of $100, compared with a recent price of $90.27.

Trillium Asset Management LLC purchased a new position in shares of Merit Medical Systems, Inc. (NASDAQ:MMSI - Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund purchased 88,038 shares of the medical instruments supplier's stock, valued at approximately $6,105,000. Trillium Asset Management LLC owned 0.15% of Merit Medical Systems at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Los Angeles Capital Management LLC acquired a new position in Merit Medical Systems in the fourth quarter valued at approximately $25,000. Torren Management LLC bought a new position in Merit Medical Systems in the fourth quarter valued at approximately $38,000. Covestor Ltd grew its holdings in Merit Medical Systems by 252.6% during the 4th quarter. Covestor Ltd now owns 469 shares of the medical instruments supplier's stock worth $41,000 after acquiring an additional 336 shares during the period. Danske Bank A S acquired a new stake in Merit Medical Systems during the 3rd quarter worth $42,000. Finally, Quarry LP raised its position in shares of Merit Medical Systems by 185.9% during the 3rd quarter. Quarry LP now owns 526 shares of the medical instruments supplier's stock valued at $44,000 after acquiring an additional 342 shares during the last quarter. 99.66% of the stock is owned by institutional investors.

Merit Medical Systems Price Performance

Shares of MMSI stock opened at $90.27 on Friday. The company has a quick ratio of 2.79, a current ratio of 4.20 and a debt-to-equity ratio of 0.44. Merit Medical Systems, Inc. has a 12-month low of $59.74 and a 12-month high of $94.75. The firm has a fifty day moving average of $76.93 and a 200-day moving average of $72.44. The firm has a market capitalization of $5.39 billion, a price-to-earnings ratio of 37.30, a price-to-earnings-growth ratio of 2.31 and a beta of 0.49.

Merit Medical Systems (NASDAQ:MMSI - Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The medical instruments supplier reported $1.19 EPS for the quarter, topping the consensus estimate of $0.96 by $0.23. The business had revenue of $418.84 million for the quarter, compared to the consensus estimate of $405.25 million. Merit Medical Systems had a return on equity of 13.75% and a net margin of 9.22%.The firm's revenue was up 9.5% compared to the same quarter last year. During the same quarter last year, the business posted $1.01 EPS. Merit Medical Systems has set its FY 2026 guidance at 4.250-4.350 EPS. On average, equities research analysts forecast that Merit Medical Systems, Inc. will post 3.81 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on MMSI shares. Needham & Company LLC increased their price target on Merit Medical Systems from $90.00 to $101.00 and gave the company a "buy" rating in a research note on Friday, July 31st. Canaccord Genuity Group upped their price objective on Merit Medical Systems from $85.00 to $94.00 and gave the company a "buy" rating in a report on Friday, July 31st. Robert W. Baird set a $98.00 target price on Merit Medical Systems in a research note on Friday, July 31st. JPMorgan Chase & Co. boosted their target price on Merit Medical Systems from $77.00 to $95.00 and gave the stock an "overweight" rating in a research report on Friday, July 31st. Finally, Raymond James Financial reaffirmed an "outperform" rating and issued a $100.00 price target on shares of Merit Medical Systems in a research note on Friday, July 31st. Eight equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $100.00.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company's product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.

Want to see what other hedge funds are holding MMSI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merit Medical Systems, Inc. (NASDAQ:MMSI - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source